Summer is here, catch up on our latest top highlights!
07 / 07 / 2022
By Explicyte
Press release & events
|
|
Explicyte is very proud to have granted Domain Therapeutics the exclusivity on data related to GPCR implicated in immunoresistance, in order to develop innovative, first-in class cancer therapies.
|
|
|||||
|
Thanks to its certified partnerships, Explicyte now offers:
|
Led in collaborations with renowned researchers, many of our works underlining Explicyte’s expertise and strengths were recently published in peer-reviewed journals.
|